An officer of Dyne Therapeutics, Inc. filed a Form 144 notice on November 13, 2026, disclosing a proposed sale of 5,513 shares of common stock through Stifel Nicolaus & Company Inc.

Key Highlights

  • Seller: John Cox, identified as an officer of Dyne Therapeutics, Inc.
  • Shares proposed for sale: 5,513 shares of common stock, with an aggregate market value of $92,751.00.
  • Source of shares: 11,250 shares acquired on November 13, 2026, through restricted stock units from the issuer as equity compensation.
  • Broker: Stifel Nicolaus & Company Inc., 501 N Broadway, St. Louis, MO 63102, with an approximate sale date of November 13, 2026, on the Nasdaq.
  • Shares outstanding: 186,746,431 shares of common stock outstanding, according to the filing.
  • Prior sales: Cox sold 5,658 shares of common stock on September 8, 2026, for gross proceeds of $106,844.00, within the past three months.

John Cox Proposes Common Stock Sale Under Rule 144 at Dyne Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 13, 2026, John Cox, an officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), proposed to sell 5,513 shares of the company's common stock. The filing lists an aggregate market value of $92,751.00 for the shares to be sold. The designated broker for the transaction is Stifel Nicolaus & Company Inc., located at 501 N Broadway, St. Louis, MO 63102.

The filing discloses that the shares to be sold were derived from an acquisition of 11,250 shares on November 13, 2026, through restricted stock units granted by the issuer, with payment described as equity compensation. Dyne Therapeutics, Inc. is headquartered at 1560 Trapelo Road, Waltham, Massachusetts 02451. The filing reports 186,746,431 total shares of common stock outstanding.

As required by Form 144, the filing also discloses sales by Cox during the prior three months. According to the notice, Cox sold 5,658 shares of common stock on September 8, 2026, for gross proceeds of $106,844.00. The notice was signed by Azad Daswani as a duly authorized representative of Stifel, acting as attorney-in-fact for John Cox, and dated November 13, 2026.

What Was Disclosed

Dyne Therapeutics officer John Cox filed a Form 144 notice proposing the sale of 5,513 shares of common stock acquired via restricted stock units, with an aggregate market value of $92,751.00, through Stifel Nicolaus & Company on the Nasdaq.